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EP2 receptor antagonism reduces 
peripheral and central hyperalgesia 
in a preclinical mouse model of 
endometriosis
Erin Greaves1, Andrew W. Horne1, Helen Jerina2, Marta Mikolajczak2, Lisa Hilferty1, 
Rory Mitchell2, Sue M. Fleetwood-Walker2 & Philippa T. K. Saunders3
Endometriosis is an incurable gynecological disorder characterized by debilitating pain and the 
establishment of innervated endometriosis lesions outside the uterus. In a preclinical mouse model 
of endometriosis we demonstrated overexpression of the PGE2-signaling pathway (including COX-2, 
EP2, EP4) in endometriosis lesions, dorsal root ganglia (DRG), spinal cord, thalamus and forebrain. 
TRPV1, a PGE2-regulated channel in nociceptive neurons was also increased in the DRG. These findings 
support the concept that an amplification process occurs along the pain neuroaxis in endometriosis. 
We then tested TRPV1, EP2, and EP4 receptor antagonists: The EP2 antagonist was the most efficient 
analgesic, reducing primary hyperalgesia by 80% and secondary hyperalgesia by 40%. In this study we 
demonstrate reversible peripheral and central hyperalgesia in mice with induced endometriosis.
Endometriosis is a chronic gynecological disorder affecting 176 million women worldwide1 associated with 
chronic pain and infertility. Current therapies include invasive surgery, drugs that suppress endogenous hor-
mones2 and non-steroidal anti-inflammatory drugs (NSAIDs) all of which have unwanted side effects. Better 
treatments for endometriosis-associated pain are needed but their development has been hampered by the lack 
of a robust preclinical model that fully reproduces the altered pain perception experienced by women with 
endometriosis.
Endometriosis is caused by the presence of endometrial-like tissue (endometriosis lesions) outside of the 
uterine cavity3. An association between small nerve fiber infiltration of endometriosis lesions and increased cen-
tral and peripheral pain has been described (reviewed in ref. 4). Alterations in pain perception in women are 
thought to involve release of inflammatory mediators and neuropeptides by efferent peripheral nerve endings5, an 
increase in the sensitivity of nociceptive neurons6, and peripheral hyperalgesia. Continuous input from peripheral 
afferents can also trigger spinal hyper-excitability (central sensitization)7 resulting in increased pain perception, 
secondary hyperalgesia and allodynia8. Prostaglandin E2 (PGE2) is a well-established mediator of inflammation 
and nociception in inflammatory9,10 and neuropathic pain conditions11 and synthesis of prostaglandins within 
endometriosis lesions has previously been reported12–15. As the association of PGE2 signaling and endometriosis 
is well established we chose to validate this pathway as a target for pain attenuation in our mouse model.
A rat model of endometriosis exhibits vaginal hyperalgesia and increased abdominal muscle activity16–18. 
Recently, a study utilizing the same rat model demonstrated increased hyperalgesia in response to von Frey fil-
aments, although an increase was also observed in the sham group19. Another model using autologous trans-
plantation of endometrial tissue onto the gastrocnemius muscle20 has proved useful for the identification of 
pronociceptive molecules that may be relevant in endometriosis21. Our murine model of endometriosis uses 
decidualized endometrial tissue injected (rather than sutured) into the peritoneum of recipient mice22. Resultant 
lesions phenocopy those in women; they are vascularized, innervated, infiltrated by macrophages and also exhibit 
oestrogen-dependent regulation of vascular-nerve and macrophage-nerve interactions23,24. The aim of our study 
1MRC Centre for Reproductive Health, The University of Edinburgh, Queen’s Medical Research Institute, 47 Little 
France Crescent, Edinburgh EH16 UK. 2Centre for Integrative Physiology, The University of Edinburgh, Hugh 
Robson Building, 15 George Square, Edinburgh EH8 UK. 3MRC Centre for Inflammation Research, The University of 
Edinburgh, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 UK. Correspondence and 
requests for materials should be addressed to E.G. (email: egreaves@ed.ac.uk)
received: 19 July 2016
accepted: 06 February 2017
Published: 10 March 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:44169 | DOI: 10.1038/srep44169
was to determine if mice with induced endometriosis exhibit peripheral (abdominal) and central (secondary/
referred) hyperalgesia and to test compounds targeting prostaglandin receptors to validate this model as a plat-
form for preclinical testing of compounds to treat pain.
Results
Induction of endometriosis lesions resulted in altered pain-associated behaviors. We confirmed 
lesions in 90% of endometriosis mice (Endo) and those that we did not recover lesions from were excluded 
from our analysis. The average number of lesions recovered was 1.9 (Supplementary Table 1). Endo mice had 
significantly higher levels of abdominally-directed licking (Fig. 1a) and decreased exploratory activity (Fig. 1b) 
compared to controls (p < 0.001). Endo mice had significantly lower mechanical withdrawal thresholds for von 
Frey filaments, not only on the abdomen (Fig. 1c) but also on the hind-paws (Fig. 1d; p < 0.05 and p < 0.01, 
respectively). We found no correlation between mechanical allodynia (hypersensitivity) and number of lesions in 
mice with endometriosis (Supplementary Fig. 1a,b)
Over-representation of the PGE2 signaling pathway and nociceptive ion channels in endo-
metriosis lesions and in the nervous system of mice with endometriosis. Consistent with our 
previous studies22–24 endometriosis-like lesions were recovered from the walls of the parietal peritoneum and 
the visceral peritoneum covering the uterus, gut, and intestines; mesentery associated with the gut and intes-
tines; adipose tissue associated with the kidney; and underneath the kidneys. EP2, EP4, cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2) were significantly increased in endometriosis lesions compared to 
Figure 1. Behavior testing in control and endometriosis mice. Endometriosis mice, together with 
ovariectomised, estradiol-treated sham recipients, with or without i.p injection of PBS, and naïve controls 
were scored for general behaviors indicative of discomfort that might be associated with pelvic pain. (a) Shows 
abdominally directed licking (average number of grooming events recorded by two observers over two 5 min 
periods) was significantly increased in endometriosis mice (n = 5) compared to estradiol-treated (OVX + E2; 
n = 3, OVX + E2 + PBS; n = 6) and naïve controls (n = 7). (b) Shows that exploratory activity (average 
number of open-field tunnel entries recorded by two observers was significantly reduced in endometriosis 
mice (n = 9) compared to estradiol-treated (OVX + E2; n = 6, OVX + E2 + PBS; n = 6) and naïve controls 
(n = 11). Mechanical withdrawal threshold, shown by von Frey filament testing, was also measured on the 
lower abdomen and plantar hind-paw of endometriosis mice (n = 6), OVX + E2, OVX + E2 + PBS (n = 6) and 
naïve controls (n = 7). For quantitative sensory testing, von Frey filaments were applied to caudal regions of 
the abdomen; (c and d) show that withdrawal thresholds (g = grams) for both abdomen and paw testing were 
significantly decreased in endometriosis mice compared to the other groups. Statistical analysis was performed 
using a one-way ANOVA and Newman-Keuls post-hoc test (a and b) or a Kruskall-Wallis test and Dunn’s 
multiple comparison test. *p < 0.05. **p < 0.01, ***p < 0.001.
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the peritoneum of naive mice (NP) or mice with endometriosis (EP; p < 0.01; Supplementary Fig. 2a–d); EP2, 
EP4, COX-1 and COX-2 proteins were immunolocalised to glandular and stromal cells in lesions and mesothe-
lial cells in the peritoneum (Supplementary Fig. 2). PGE2 concentrations in the peritoneal fluid of Endo mice 
were significantly increased (p < 0.05; Supplementary Fig. 2E). mRNA concentrations of EP1 and EP3 were 
unchanged (Supplementary Fig. 2f,g). EP2, Cox-1, Scn11a and Trpv1 mRNA concentrations were significantly 
increased in dorsal root ganglia (DRG; clusters of cell bodies of afferent sensory neurons that transmit noxious 
stimuli from the periphery to the spinal cord) from endometriosis mice (p < 0.05; Fig. 2a–d); EP4 and Cox-2 
were unchanged (Supplementary Fig. 3c,d). Trpv1 mRNA was also increased in the DRGs from OVX + E2 mice. 
Dual immunofluorescence showed that in small DRG cells expressing peripherin (a marker for small unmy-
elinated sensory neurons; C-fibre nociceptors), the proportion that were immunopositive for TRPV1 was sig-
nificantly increased in Endo mice compared to naïve and OVX + E2-treated controls (p < 0.05; Fig. 2e,f). The 
proportion of TRPV1-immunopositive neurons in DRG that express EP2 was also increased in these animals 
(Supplementary Fig. 3e,f). Mice with endometriosis had significantly increased concentrations of COX-2 pro-
tein in the spinal dorsal horn (p < 0.001), the thalamus (p < 0.001) and the anterior cingulate cortex of the brain 
(p < 0.001; Fig. 2f,i). All of these changes would be expected to contribute to pain hypersensitivity.
Pre-clinical testing and stratification of potential therapies identified EP2 as a key target. 
Figure 3 indicates that injection of the TRPV1 inhibitor JNJ 17203212 (Fig. 3a,b) or the EP4 antagonist L-161982 
(Fig. 3c,d), did not reverse abdominal or paw hyperalgesia to a statistically significant extent. Administration of 
the EP2 antagonist TG6-10-1 resulted in a statistically significant reversal of mechanical allodynia as tested on the 
abdomen (p < 0.05) at 45 mins post administration but this did not reach significance for the hind paw (Fig. 3e,f). 
Time-course graphs are shown in Supplementary Fig. 4. Results were extended using injection (Fig. 3g,h) or oral 
administration (Fig. 4a,b) of a second EP2 antagonist (PF-04418948)25 and this reduced allodynia in both abdo-
men and hind-paw tests (p < 0.001 using either route). Oral administration resulted in striking, time dependent, 
and significant impacts (Fig. 4a,b, p < 0.001).
Discussion
The re-purposing of drugs and the development of novel treatments for endometriosis-associated pelvic pain has 
been limited by the paucity of accessible pre-clinical models. In this study we tested pain responses in a mouse 
model of endometriosis that phenocopies interactions between endometriosis lesions and peritoneal tissue22,24 
identified in humans. Endometriosis (Endo) mice exhibited increased levels of abdominally-directed grooming, 
a reduction in normal exploratory behavior and reduced mechanical withdrawal thresholds on both the abdomen 
and plantar hind-paw. The rodent models reported by Berkley, and by Levine and Giudice, both report evidence 
of hyperalgesia16,20,26,27. These models involve the artificial implantation of uterine tissue (full thickness i.e. endo-
metrium plus myometrium) onto the mesenteric arteries of the small intestine and the gastrocnemius muscle, 
respectively. Therefore the microenvironment of the endometriosis lesion created in these models may not closely 
mirror that of the peripheral lesions in women.
PGE2 is increased in the peritoneal fluid of patients with endometriosis28, this up-regulation results from 
induced expression of cyclooxygenase-2 (COX-2) in endometriotic tissue. PGE2 is thought to be a key player 
in the pathophysiology of endometriosis and studies have shown that inhibition of COX-2 decreases survival, 
migration and invasion of endometriotic cells13. The same authors demonstrated that inhibition of EP2 and EP4 
can inhibit the epithelial and stromal cell invasion via suppression of matrix metalloproteinases29. Attenuation 
of PGE2 signaling via lipoxin A4 can also modulate disease progression by attenuation of pro-inflammatory and 
angiogenic mediators30. A recent study using xenografted endometriotic cell lines in a nude mouse model of 
endometriosis demonstrated that dual inhibition of EP2 and EP4 could attenuate mechanical hyperlagesia of the 
pelvic floor via suppression of pro-inflammatory mediators in dorsal root ganglia31, however the authors did not 
test secondary hyperalgesia or analyze changes in the central nervous system.
In our mouse model we confirmed that the prostaglandin E signaling pathway was over-expressed in the 
pelvic cavity of our Endo mice and concentrations of PGE2 were increased in their peritoneal fluid. Release of 
PGE2 at sites of peripheral inflammation can contribute to pain hypersensitivity by lowering the threshold and 
enhancing the excitability of nociceptor sensory fibers32. This occurs at least in part via EP receptor-mediated 
activation of intracellular kinases in the nociceptor terminal that causes phosphorylation of the nociceptive 
ion channel TRPV133,34 and an up-regulation of Nav1.9 voltage-gated sodium channel (SCN11A)35, which is 
then transported to peripheral nerve terminals to contribute to increased excitability7. We detected a significant 
increase in expression of EP2, COX-1 and both TRPV1 and SCN11A ion channels in the DRGs of mice with 
endometriosis. This parallels observations of increased COX-1 and COX-2 in TRPV1-positive DRG cells in other 
models of inflammatory hyperalgesia36. TRPV1-immunoreactivity was increased in small, peripherin-positive, 
nociceptive neurons in DRG of mice with endometriosis and EP2 expression was further increased in these cells. 
All of these findings are consistent with the development of sensory neuron hyperexcitability in our mice. The 
possibility of some additional role of prostaglandin signaling in non-neuronal cells, as seen in some other pain 
models37 cannot be excluded. Elevated TRPV1 expression in small DRG cells innervating pelvic regions in mice 
with endometriosis is consistent with our previous findings that TRPV1 mRNA is elevated in peritoneal lesions 
from women with endometriosis38.
In this study, assessment of COX-2 expression in CNS regions within the pain-processing pathway revealed 
striking increases in expression at spinal, thalamic and cortical levels. COX-2 expression in the CNS is estab-
lished as a sensitive and responsive biomarker of centralized inflammatory pain39–41 and is an important finding 
consistent with the inflammatory pain and widespread central sensitization as experienced by women with endo-
metriosis. The phenomenon of central sensitization42 has been postulated as a key contributor to the co-morbid 
pain syndromes experienced by women with the condition4. Central sensitization is described as a maladaptation 
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Figure 2. Molecular changes in the nervous system of mice with endometriosis. Expression of the 
PGE2 pathway and nociceptive ion channels is elevated in the DRGs, spinal cord and brain of mice with 
endometriosis. (a–d) QPCR analysis of the prostaglandin E receptor 2(a) EP2, (b) COX-1 and nociceptive ion 
channels (c) SCN11A and (d) TRPV1 in L5-L6 DRGs from mice with endometriosis (n = 9) compared to naïve 
(n = 7) and OVX + E2 control mice (n = 6). RQ: Relative quantification. Values were normalized to a single 
naïve DRG sample given the arbitrary value of one. (e,f) Dual label immunofluorescence was carried out to 
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of the CNS resulting from continued or repetitive input from nociceptors, in endometriosis it is likely that this 
input is provided by afferent nerve fibers innervating endometriosis lesions. One of the first steps in this process 
of central sensitization is an increase in expression of genes encoding neurotrophins, neuropeptides and ion 
channels critical in sensing and detecting noxious stimuli8. In the model of endometriosis generated by Berkley et 
al, rats exhibit vaginal hyperalgesia26 and it is argued by the authors that this finding suggests central sensitization 
as an underlying factor because spinal segments associated with the induced endometriosis cysts are distant from 
spinal segments receiving input from the vagina43,44. Using this same model a decrease in μ -opioid and NMDA 
receptor immunoreactivity in the periaqueductal gray area of the brain was detected in rats with endometriosis 
compared to controls. Torres-Reverón et al suggested that a decrease in NMDA receptor expression could be an 
attempt to homeostatically regulate pain perception, whilst a decrease in μ -opioid receptor expression suggests 
decreased modulatory activity of opioid receptors that could contribute to hyperalgesia in the condition45. We 
have also documented molecular alterations in the CNS of mice with endometriosis and we believe this as an 
important step change in our understanding of endometriosis-associated pain.
Having demonstrated amplified pain behaviors, we tested therapeutic strategies for reversal of mechanical 
allodynia. The effects of TRPV1 inhibition were modest, whilst antagonism of EP2, particularly following oral 
administration of the highly selective antagonist PF-04418948 had pronounced effects on peripheral and second-
ary hyperalgesia. This is consistent with reports that EP2 null mice do not develop spinal hyperalgesia following 
induced peripheral inflammation46. In a recent study, the effect of a mixture of EP2/EP4 antagonists had a modest 
impact on pelvic floor hyperalgesia in mice which may either reflect the limited specificity of the antagonists 
tested or use of human endometriotic cell lines (not intact tissue fragments) in recipient mice lacking a full com-
plement of immune cells31. In our hands, the selective EP4 antagonist L-161982, did not reverse the sensitivity to 
mechanical stimulation.
In summary, we show that induction of endometriosis in mice with an intact immune system is associated 
with maladaptation of the CNS, consistent with central sensitization4. We have demonstrated striking reversal 
of both peripheral and secondary hyperalgesia via EP2 antagonism. In conclusion, we present evidence that a 
murine model of endometriosis displaying local and central sensitization can be used for pre-clinical testing of 
therapeutics for endometriosis-associated pain.
Methods
Mouse model of endometriosis. Experiments were performed in accordance with the Guidelines of the 
Committee for Research and Ethical Issues of the International Association for the Study of Pain. Experiments 
were performed under licensed approval from the UK Home Office (London). C57BL/6 mice (Harlan 
Laboratories; Derby, UK) were given access to food and water ad libitum, ambient temperature and humidity 
were 21 °C and 50% respectively. Endometriosis was induced in the mice as previously described22. In brief, the 
endometrium of syngeneic donor mice underwent hormonal manipulation and induction of decidualization 
using an in-house protocol to model endometrial differentiation, breakdown and repair47: detailed analysis of tis-
sue samples has shown that progesterone withdrawal (removal of P4 pellet) results in rapid induction of hypoxia, 
tissue breakdown and induction of angiogenic genes47,48. Endometrial tissue (~6 hours post-progesterone with-
drawal) was recovered by opening the horn and scraping with a scalpel. Approximately 40 mg tissue (equivalent 
to one decidualized horn) was suspended in 0.2 ml PBS and injected into the peritoneal cavity of ovariectomised 
recipient mice that were supplemented with 500 ng Estradiol Valerate (EV). This supplementation was maintained 
by subcutaneous injection of 500 ng EV every 3 days (modification of previously published model). After allowing 
lesions to form over 21 days behavioral assessments were performed.
Behavioral assessments. All behavioral tests were performed starting 21 days after endometrio-
sis induction on 2 consecutive days (day 21 and 22). Mechanical allodynia was measured using calibrated 
Semmes-Weinstein von Frey filaments (Stoelting, Wood Vale, IL), according to the manufacturer’s instructions. 
Von Frey filaments were applied to the skin perpendicular to the plantar surface of the hindpaws or to the lower 
abdomen, as in refs 49–51. Filaments were applied to the abdomen or hind-paw ten times, force in grams (g) 
of the filament evoking a withdrawal response in 50% of cases was recorded. Initial testing of the abdomen in 
naïve mice indicated lower thresholds in more caudal regions, in agreement with a previous report50. For the 
following spontaneous behavior tests mice were placed in observation boxes for two 5 min periods and man-
ually observed by two independent investigators (one blinded to experimental group). Periods of spontaneous 
identify TRPV1 expression (red) in L5-6 DRG cells co-expressing peripherin (green). (e) Shows typical confocal 
images for TRPV1 and peripherin from naïve, OVX + E2-treated sham-recipient and endometriosis mice (field 
of view, 160 × 160 μ m). Total cells counted were 330, 320, and 543, accumulated from three different naïve, 
OVX + E2-treated and endometriosis mice in each case. (f) Shows a bar chart that summarizes % expression 
of TRPV1 in peripherin-positive cells and indicates that the number of TRPV1 + peripherin + small DRG 
cells is significantly increased in mice with endometriosis. (g–i) Images (i) show representative examples of 
COX-2 (top panel; 80 kDa) and GAPDH (bottom panel; 36 kDa) expression as analyzed using Western blot 
in (g) spinal cord, (h) thalamus, (i) and anterior cingulate cortex of endometriosis mice, OVX + E2-treated 
sham-recipients and naïve controls, n = 5-6 for all groups. (ii) Graphs showing COX-2: GAPDH densitometric 
ratio derived from quantitative densitometry of films. Both images and bar charts indicate marked elevation of 
COX-2 expression in each region. No changes were observed in OVX + E2-treated and naïve controls. Statistical 
analysis was performed using a one-way ANOVA and Tukey’s post comparison test. *p < 0.05, **p < 0.01, 
***p < 0.001.
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Figure 3. Pre-clinical testing of potential therapeutics in a mouse model of endometriosis. Graphs depict 
50% mechanical withdrawal thresholds for von Frey filaments (g = grams) applied to abdomen or hindpaw 
of mice with endometriosis or naïve controls, n = 5 all groups. The time-point showing maximal reversal of 
pain is shown for each antagonist. (a) Effects of the TRPV1 inhibitor JNJ 17203212 (30 mg/kg ip), 30 mins 
post-injection on abdominal withdrawal responses in mice with endometriosis compared to naïve mice. 
(b) Shows corresponding results from hindpaw. Concurrently measured naïve values were 0.55 ± 0.17 g and 
www.nature.com/scientificreports/
7Scientific RepoRts | 7:44169 | DOI: 10.1038/srep44169
abdominally directed licking (an element of normal grooming behavior52) were recorded and an average gen-
erated. Excessive abdominally-directed licking has been reported to represent a useful biomarker of abdominal 
visceral pain46. Each time a mouse exhibited abdominal grooming was recorded as an event. The matrix of brain 
regions activated during pain includes areas impacting on affective behaviors, corresponding to the anxiety- and 
depression-like signs associated with chronic pain states53. Paradigms of altered affective sate in rodent pain 
models include reduced exploratory behavior54. Exploratory activity here was recorded in a modification of the 
open-field setting55,56, with mice retained within their home box with a cardboard tunnel in the centre of the 
enclosure; open-field tunnel entries were manually recorded by two independent investigators (one blinded to 
experimental group).
Experimental groups and sample collection. Four groups of mice were analysed; (i) naïve controls 
(no surgical procedures; n = 9), (ii) OVX + E2 controls (n = 9), for which, mice were ovariectomised and given 
E2 valerate (Sigma, UK), s.c. 500 ng in sesame oil every 2 days to mirror the surgical and hormonal status of the 
Endo mice; (iii) OVX + E2 + PBS controls (n = 6); as in group ii plus i.p injection of PBS, to mirror injection of 
tissue as in Endo mice (iv) endometriosis mice (Endo mice; as group iii, with ‘menstrual’ donor material in PBS 
injected i.p (n = 18)). On day 23 mice were culled and the following samples recovered: peritoneal fluid (PF, 
recovered as in ref. 57 by injecting 3 ml ice cold PBS into the peritoneal cavity followed by gentle massage and 
recovery (approximately 2 ml was recovered from the injected 3 ml). PF was then centrifuged and frozen), peri-
toneal biopsy, endometriotic lesions, L5-L6 DRGs, lumbar spinal cord, thalamus and anterior cingulate cortex. 
Samples were collected into RNAlater (Applied Biosystems, Warrington, UK) and frozen, neutral-buffered for-
malin prior to paraffin embedding for immunohistochemical analysis (uterus, peritoneum, and endometriosis 
lesions) or frozen on dry ice prior to sectioning and immunofluorescence staining (DRG) or protein extraction 
for Western blot analysis (spinal cord and brain). Endometriotic lesions were recognized as red, brown or white 
tissue deposits on the visceral or parietal peritoneum and were carefully dissected away from any surrounding fat 
or peritoneum. The presence of glands plus stroma in suspected lesions were confirmed by haematoxylin/eosin 
staining. Biopsies that did not contain both glands and stroma were not included in further analysis.
Antagonists. Agents for i.p. injections were dissolved in 10% dimethylsulphoxide, 50% PEG-400, 40% 
de-ionised H20 and injected in a volume of 100 μ l/25 g using 30 mg/kg JNJ 17203212 (TRPV1 antagonist), 
10 mg/kg TG6-10-1 (EP2 antagonist; Calbiochem)58, 10 mg/kg PF-0441894825 (EP2 antagonist; Abcam),10 mg/
kg L-161982 (EP4 antagonist; Abcam). Von Frey testing was performed at 30, 45 and 60 minutes post injection: 
for PF-0418948, testing was also carried out at 75 minutes). PF-04418948 (10 mg/kg in 0.5% w/v methylcellulose 
+0.1% V/V Tween-20 in purified water) was also administered as an oral gavage and the von Frey test performed 
every 15 mins starting at 30 mins.
Quantitative real time PCR. RNA was extracted from control uterine biopsies recovered from naïve mice, 
peritoneal biopsies from naïve and endometriosis mice, endometriosis lesions and dorsal root ganglia using an 
RNeasy kit (QIAGEN) according to the manufacturers instructions. RNA was quantified using a NanoDrop ND 
1000. Quantitative PCR was performed as detailed in refs 59,60; briefly, cDNA was synthesized using SuperScript 
VILO enzyme (Invitrogen) with 100ng starting template. PCRs were performed using Roche Universal Probe 
Library (Roche Applied Science) using primer sequences detailed in Supplementary Table 2. 18S was used as a 
reference gene. Thermal cycling was performed on a 7900 Fast real-time PCR machine. Data was analysed with 
RQ manager software (Applied Biosystems) using the ∆ ∆ Ct method; samples were normalised to a uterine con-
trol sample.
Immunodetection. Single antigen immunohistochemistry was performed according to standard proto-
cols47,61 with citrate antigen retrieval.
11.25 ± 1.44 g respectively for abdomen and hindpaw. In both tests, withdrawal thresholds were significantly 
lower in mice with endometriosis (Endo + Vehicle) than in naïve controls or in naïve animals treated with the 
drug (Naïve + JNJ; p < 0.01 and p < 0.001). This difference was modestly but not significantly attenuated by 
JNJ 17203212, which had no discernible effect on the responses of naïve animals. (c) Effects of the selective 
EP4 antagonist L-161982 (10 mg/kg ip) 30 mins post i.p injection on abdominal and (d) hindpaw mechanical 
withdrawal thresholds. Naïve values were 0.39 ± 0.07 g and 9.43 ± 1.43 g. In both tests, thresholds were 
significantly lower in mice with endometriosis than in naïve animals treated with the drug (p < 0.001). L-161982 
had no discernible effect on hypersensitivity in mice with endometriosis or in naïve animals. (e) Effect of the 
EP2 antagonist TG6-10-1 (10 mg/kg, ip), on abdominal and (f) hindpaw mechanical withdrawal thresholds 
at 45 mins post i.p injection. Naïve values were 0.31 ± 0.11 g and 9.69 ± 1.62 g. In both tests, thresholds were 
significantly lower in mice with endometriosis compared to naïve controls or in naïve animals treated with 
the drug (p < 0.01 and p < 0.001). This difference was significantly reversed by TG6-10-1 in abdominal tests 
(p < 0.05). TG6-10-1 also induced a modest but not statistically significant pain reversal in paw tests. The 
highly selective EP2 antagonist PF-04418948 (10 mg/kg, i.p) significantly attenuated both (g) abdominal and 
(h) hindpaw mechanical hypersensitivity in mice with endometriosis (p < 0.001) 45 mins post injection. There 
was no discernible effect of PF-04418948 in naïve animals. Naïve values were 0.48 ± 0.05 g and 8.77 ± 0.51 g. 
Statistical analysis was performed using a one-way ANOVA and Tukey’s post comparison test. *p < 0.05, 
**p < 0.001, ***p < 0.001.
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Dual immunofluorescence. Dorsal root ganglia (DRGs) were embedded in OCT (CellPath) and frozen on dry 
ice. Sixteen μ m cryostat sections were blocked for 1 hour at room temperature then incubated with primary anti-
bodies (Supplementary Table 3). Specificity of the TRPV1 antibody has been previously established62. Secondary 
antibodies, from Molecular Probes or Sigma-Aldrich, goat anti-chicken Alexafluor 488 (1:1000), goat anti-guinea 
pig AlexaFluor 568 (1:1000) or goat anti-guinea-pig CF405A (1:1000) were applied for 1 hour. Sections were 
mounted in ProLong® Gold Antifade (Life Technologies). Confocal images were acquired at x20 magnification 
using a Nikon A1R microscope and ImageJ software was used to quantify co-staining. Standard controls omitting 
primary antibodies were immunonegative.
Prostaglandin E2 (PGE2) ELISA. Approximately 2 ml of the PF was collected into tubes containing indo-
methacin (10 μ M) to prevent ex vivo PGE2 metabolism. PGE2 levels were analyzed using DetectX® prostaglandin 
E2 enzyme immunoassay kit (Arbor Assays, MI, USA).
Western blotting. Tissue samples were collected into sealable tubes and frozen on dry ice, and then sub-
sequently homogenized in Laemmli buffer, heated to 80 °C for 5 min and centrifuged. Aliquots of lysate super-
natant were analysed using the NuPage XCell SureLockTM Minicell gel electrophoresis system (Invitrogen) with 
approximately 12 μ g protein loaded per lane. Membranes were incubated overnight at 4 °C in 2% non-fat dried 
milk in 0.1 M PBS with 0.1% Tween-20, containing anti-COX-2 antibody (Supplementary Table 3)63. Membranes 
were washed and incubated for 50 min at room temperature with peroxidase-conjugated donkey anti-rabbit anti-
body (Chemicon, 1:20,000) and detected by peroxidase-linked enhanced chemiluminescence. Membranes were 
re-probed with mouse monoclonal anti-GAPDH (Supplementary Table 2). Films were scanned and band inten-
sities were quantified by densitometry using ImageJ.
Statistical analysis. Statistical analysis used a one-way ANOVA with a Newman Keuls or Tukey’s test, or 
a Kruskal Wallis with a Dunn’s multiple comparison test. A p value of less than 0.05 was considered significant. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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